These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19216325)

  • 1. [Nutrition-obesity. Rimonabant and cardiovascular risk factors].
    Vincent M; Golay A
    Rev Med Suisse; 2009 Jan; 5(185):49-52. PubMed ID: 19216325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
    Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
    [No Abstract]   [Full Text] [Related]  

  • 4. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
    Kintscher U
    Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
    Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
    Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
    Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
    Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE).
    Boesten JE; Kaper J; Stoffers HE; Kroon AA; van Schayck OC
    Fam Pract; 2012 Oct; 29(5):521-7. PubMed ID: 22389428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
    Di Marzo V
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
    [No Abstract]   [Full Text] [Related]  

  • 9. Less weight or more hype with rimonabant?
    Drug Ther Bull; 2007 Jun; 45(6):41-3. PubMed ID: 17583228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic risk factors, drugs, and obesity.
    Padwal R; Majumdar S
    N Engl J Med; 2006 Mar; 354(9):974-5; author reply. PubMed ID: 16510755
    [No Abstract]   [Full Text] [Related]  

  • 11. Pleiotropic effects of rimonabant: clinical implications.
    Després JP
    Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism.
    Andrikopoulos GK; Tzeis S
    Angiology; 2008; 59(2 Suppl):44S-8S. PubMed ID: 18635590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Boekholdt SM; Jukema JW; Peters RJ
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on rimonabant--a selective cannabinoid CB1 antagonist.
    Boyd ST; Fremming BA
    Ann Pharmacother; 2006 May; 40(5):994. PubMed ID: 16638915
    [No Abstract]   [Full Text] [Related]  

  • 16. [The endocannabinoid system and treatment of obesity].
    Aronsen L
    Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
    Watson KE
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S37-42. PubMed ID: 17934393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
    Steinberg BA; Cannon CP
    Am J Cardiol; 2007 Dec; 100(12A):27P-32P. PubMed ID: 18154743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
    Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.